(CLLS) Cellectis S.A. Business Model Canvas Research

Iovance Biotherapeutics is one of Cellectis S.A.’s strategic partners, and the link widens its cell therapy collaboration base. It also gives external support to Cellectis S.A.’s platform and pipeline, which matters in a field where peer validation can drive partner interest and deal flow.

• Strategic partner: Iovance Biotherapeutics
• Broadens cell therapy collaboration
• Supports external platform validation

Cytovia Therapeutics served as a dedicated R and D collaborator, helping Cellectis share early discovery work and de-risk preclinical programs across a platform built for multiple product candidates. This kind of partner fit matters when one company is advancing several gene-edited assets at once.

• Shared early-stage discovery
• Supports multiple programs
• Fits platform model

Cellectis S.A. uses partnership management to run its strategic alliances, with joint governance, data sharing, and milestone tracking across partner-led programs. In FY2025, these deals remained key to funding and execution leverage, since milestone payments and shared development costs help offset R&D intensity.

• Joint governance keeps partner decisions aligned
• Data sharing speeds program execution
• Milestones support non-dilutive funding

Cellectis S.A.'s Plants division keeps plant biotechnology as a second track beside oncology, using the same gene-editing know-how to work on plant systems and broaden its research base. Public filings do not disclose a separate Plants revenue line, so this activity is best seen as a strategic R&D option, not a scale business.

• Uses gene-editing expertise beyond oncology
• Diversifies Cellectis S.A.'s research pipeline
• No separate Plants revenue disclosed

Cellectis S.A. depends on scientific and clinical teams as core key resources: they drive discovery, translate lab work into manufacturing design, and keep trials moving. In complex cell therapy, human capital is the real edge, because each program needs deep research, process, and clinical know-how.

• Discovery and translational staff
• Manufacturing design support
• Clinical trial execution

Cellectis S.A. has its principal offices in Paris, France, where the company was founded in 1999. The Paris base anchors European biotech operations and makes cross-border work with partners, regulators, and research groups easier.

• Paris headquarters since 1999
• Supports European biotech operations
• Helps international collaboration

Cellectis S.A. focuses on immuno-oncology, with clinical-stage programs built for relapsed or refractory cancers where patients often have few options left. That targets high-unmet-need markets, including hematologic cancers, where the company’s allogeneic CAR-T approach aims to reach treatment-resistant patients faster and at lower manufacturing complexity than bespoke cell therapy.

• Targets hard-to-treat relapsed or refractory cancers
• Focuses on immuno-oncology, mainly CAR-T
• Built for high unmet-need markets

Cellectis S.A. has built a partnerable platform that fits strategic collaboration, and its track record with Allogene, Servier, MD Anderson, Iovance, and Cytovia shows clear external demand. That mix of repeat partners adds scientific validation and can widen the deal pipeline without Cellectis S.A. funding every program alone.

• 5 named collaboration partners
• Scientific validation from peers
• Potential for shared R&D risk

Cellectis S.A. keeps scientific support highly specialized: technical talks with partners and investigators stay active, and the company must share preclinical, clinical, and manufacturing data to back each program with evidence. This works as a trust-based, data-heavy relationship, where decisions depend on trial readouts, process quality, and regulatory-grade documentation.

• Ongoing partner and investigator talks
• Shares preclinical, clinical, manufacturing data
• Evidence-based, highly specialized support

Patients reach Cellectis S.A. therapies mainly through clinical studies, so the relationship is built around trial access, eligibility screening, treatment logistics, and safety follow-up. That matters in rare cancers, which make up about 25% of cancer cases, and in relapsed settings where standard options are few.

• Clinical-trial access drives patient contact
• Screening filters fit and safety
• Follow-up supports rare, relapsed cases

Cellectis S.A. uses scientific conferences and peer-reviewed publications to show preclinical and clinical progress to researchers, regulators, and pharma partners. These forums shape reputation and can speed deal flow by making data visible in the same venues where licensing and collaboration talks often start.

• Shares data at medical forums
• Supports partner trust
• Boosts scientific credibility

Cellectis S.A. uses public company reporting and investor calls as a direct channel to capital markets, showing pipeline progress, partnership updates, and funding needs. In its latest FY2025 reporting cycle, this disclosure helps investors judge cash runway and access to external funding for ongoing clinical work.

• Shares pipeline and deal milestones
• Signals financing needs and runway

Hospitals and cancer centers are Cellectis S.A.'s core operational customers because cell therapy trials need accredited sites for leukapheresis, infusion, and toxicity monitoring. These centers also shape commercialization: in the U.S., CAR-T use has been concentrated in a limited network of specialized treatment sites, so each new center can directly lift access and adoption.

• Trial site, infusion point, adoption gatekeeper
• Needs GMP-grade handling and monitoring
• Drives access if products reach market

Cellectis S.A.'s Plants division adds a second customer base beyond oncology: academic labs, plant research institutes, and plant biotech partners. That widens the market beyond medical R&D and can support recurring collaboration, licensing, and platform use cases.

• Targets plant science users
• Expands beyond oncology
• Supports broader market reach

Cellectis S.A. leans on researchers, clinicians, regulatory staff, and operations teams, so personnel is a core fixed cost. In biotech, talent retention matters because platform know-how sits in people, not just patents.

For 2025/2026, this cost line should stay tied to headcount, clinical execution, and GMP scale-up, with high pressure on pay, benefits, and recruitment in scarce scientific roles.

• Researchers and clinicians drive R&D.
• Regulatory staff speed approvals.
• Operations teams support GMP output.
• Retention protects platform know-how.

For Cellectis S.A., regulatory, legal, and IP costs are recurring and tied to patent filings, freedom-to-operate reviews, and FDA/EMA documentation for each clinical program. Collaboration deals also add legal and admin work, so these costs rise with every new partner, jurisdiction, and trial stage.

• Patent filings and renewals
• Regulatory dossiers and compliance
• Contract and alliance admin work

Cellectis S.A. has no reported royalty income yet; these payments only start if partnered candidates reach the market. That makes royalties a classic biotech upside stream: high-margin cash later, without building a full sales force.

• Market launch triggers royalties
• Current royalty income: 0
• Upside with low operating burden

For Cellectis S.A., this keeps value tied to partner execution, not commercial scale.

Cellectis S.A. can use academic and collaborative research grants as non-dilutive cash to fund early-stage platform and plant work. In FY2025, this matters most where external partners pay for preclinical R&D, since grants and sponsored research can reduce burn before product revenue starts.

• Non-dilutive early-stage funding
• Best fit: platform and plant research
• Often tied to sponsored projects